Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling

BACKGROUND: Gemcitabine (GEM) resistance remains a significant clinical challenge in pancreatic cancer treatment. Here, we investigated the therapeutic utility of everolimus (Evr), an inhibitor of mammalian target of rapamycin (mTOR), in targeting the Warburg effect to overcome GEM resistance in pan...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Jing, Guo, Yao, Wu, Heshui, Xiong, Jiongxin, Peng, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045370/
https://www.ncbi.nlm.nih.gov/pubmed/33849427
http://dx.doi.org/10.1186/s10020-021-00300-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045370/
https://www.ncbi.nlm.nih.gov/pubmed/33849427
http://dx.doi.org/10.1186/s10020-021-00300-8

Ejemplares similares